1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)-
Lymphoma
First Affiliated Hospital of Fujian Medical Universityprotein_peptideEarly Phase 1Dormant
C
34/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 65/ 100
Competitive context
289 Active assets in the Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINBLASTINE Intensity Therapeutics, Inc. | Phase 4 | BBB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation | Phase 4 | BBB |
BLEOMYCIN Shandong Provincial Hospital | Phase 4 | BB |
VINCRISTINE SULFATE Inhye Ahn | Phase 3 | BB |
(+)-VINCRISTINE Beth Israel Deaconess Medical Center | Phase 4 | BB |
View all 50 →
Same molecule, other indications
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →